Spleen Lymphocyte Populations and Expression of Activation Markers in Rats Treated with the Potent New Immunosuppressive Agent FK-506
Overview
Authors
Affiliations
Rats were immunized systemically with sheep red blood cells (SRBC) and treated with either FK-506 (1 mg/kg/day) or cyclosporin A (CsA) (25 mg/kg/day) for 7 days. Profound (greater than 90%) suppression of the production of splenic IgM-secreting plasma cells and circulating antibody levels was observed in animals receiving either drug. Immunosuppression was accompanied by significant increases in the incidence and absolute numbers of OX8+ (T-cytotoxic/suppressor) lymphocytes in the spleen, and there were corresponding reductions in the W3/25+:OX8 (CD4+:CD8+) ratio. The magnitude of these changes was not affected by drug combination. There were no significant alterations in B cells with either agent, whilst a small but significant increase in the incidence of macrophages was observed in all drug-treated groups. Neither FK-506 nor CsA affected IL-2 receptor (OX39) or MHC class II (OX6) antigen expression. This study demonstrates the remarkable immunosuppressive potency of FK-506 and its underlying capacity, like CsA, to affect regulatory T-lymphocyte subsets in vivo.
Peters D, Fitton A, Plosker G, Faulds D Drugs. 1993; 46(4):746-94.
PMID: 7506654 DOI: 10.2165/00003495-199346040-00009.
Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506.
Walliser P, Benzie C, Kay J Immunology. 1989; 68(3):434-5.
PMID: 2480331 PMC: 1385461.
Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506.
Kay J, Benzie C, Goodier M, Wick C, Doe S Immunology. 1989; 67(4):473-7.
PMID: 2475433 PMC: 1385316.
Woo J, Propper D, MacLeod A, Thomson A Clin Exp Immunol. 1990; 82(3):462-8.
PMID: 1702375 PMC: 1535490. DOI: 10.1111/j.1365-2249.1990.tb05472.x.
The influence of FK-506 on the thymus: an immunophenotypic and structural analysis.
Ross C, Thomson A Immunology. 1990; 70(3):398-404.
PMID: 1696242 PMC: 1384172.